Background Makuch and Simon [Sample size considerations for non-randomised comparative studies. J Chronic Dis 1980; 33: 175-81.] developed a sample size formula for historical control trials. When assessing power, they assumed the true control treatment effect to be equal to the observed effect from the historical control group. Many researchers have pointed out that the Makuch-Simon approach does not preserve the nominal power and type I error when considering the uncertainty in the true historical control treatment effect. Purpose To develop a sample size formula that properly accounts for the underlying randomness in the observations from the historical control group. Methods We reveal the extremely skewed nature in the distributions of power and type I error, obtained over all the random realizations of the historical control data. The skewness motivates us to derive a sample size formula that controls the percentiles, instead of the means, of the power and type I error.
Introduction
Randomized clinical trials (RCTs) have become the gold standard in comparing the effects between treatments. Despite the rigorous scientific basis, there are situations where RCTs are infeasible due to concerns of ethics, patient preference, cost, and regulatory acceptability. For example, the resources required by an RCT might be prohibitive for some phase II trials, which are intended to obtain preliminary data on the effectiveness of a new treatment [1] . Another example is that when evidence already exists showing the superiority of a new treatment over the standard one, it might be unethical for a RCT to assign patients to a potentially inferior treatment. One solution is to use a historical control trial (HCT), where the experimental therapy is compared with a control therapy (referred to as historical control or HC) that has been evaluated in a previously conducted trial. Because an HCT can be smaller in size and easier to conduct, it has been widely applied in clinical researches [2] [3] [4] [5] [6] [7] [8] .
Makuch and Simon [9] developed a sample size formula for HCTs with a binary outcome. In power calculation, they assumed that the observed response rate from the HC group was the true control response rate. Their formula was based on the two-sample test statistic employed in RCTs, but the power calculation only accounted for the sampling variability in the experimental group. The sample size solution was obtained through a numerical search. Using a similar idea, Dixon and Simon [10] provided a sample size formula for HCTs with exponential survival outcomes. Chang et al. [11] presented a two-stage design for phase II clinical trials with HC and continuous outcomes. More discussions about the HCT sample size calculation can be found in references [12, 13] .
The estimated sample size for an HCT is usually much smaller than that required by an RCT. Lee and Tseng [14] pointed out that the sample size reduction in HCT is largely unjustified, due to the strong assumption that the observed historical control response rate is equal to the true control response rate. They proposed a uniform power method to control the expected power, taking into account the uncertainty in the HC response rate. The resulting sample size is closer to the RCT sample size than the one based on Makuch and Simmon's (M-S) method. Korn and Freidlin [15] compared three approaches to HCT design: M-S approach, RCT approach, and one-sample approach (based on a one-sample test that the experimental treatment effect is greater than the observed HC treatment effect). The authors suggested that the RCT approach should be adopted because it preserves the unconditional power over the random HC observations.
In this study, we investigate the sample size calculation for HCT with continuous outcomes, accounting for the uncertainty caused by the unknown true HC treatment effect. We provide a unified framework for the M-S, RCT, and onesample approaches, where they are shown to either control the mean or the median of the random power and type I error, obtained over all the possible realizations of the HC data, given the true HC effect. We further demonstrate through simulation that the distributions of power and type I error are extremely skewed. This extreme skewness leads to undesirable properties of sample sizes calculated to control the means of power and type I error. One revealing example in our simulation is that with the mean power controlled at 0.8, a slight decrease in the mean type I error from 0.06 to 0.05 leads to a drastic increase in sample size from 286 to 487. This observation motivates us to develop a sample size formula that controls the percentiles, instead of the means, of the random power and type I error. To our knowledge, it is the first study done in HCT design to demonstrate the extreme skewness in the distributions of power and type I error, and to estimate sample size based on the percentiles of power and type I error. It provides researchers a sensible way to assess the risk in an HCT. The proposed formula has a closed form, which can be easily computed using a scientific calculator.
The rest of this article is organized as follows: in the section 'A unified framework,' we review the three different approaches (M-S, RCT, and one sample) to sample size calculation in HCT under a unified framework. A simulation study is conducted to demonstrate the extreme skewness in the distributions of power and type I error. In the section 'Sample size controlling the percentiles,' we present a sample size formula to control arbitrary percentiles of power and type I error. We evaluate its performance through simulation in two scenarios: an ideal scenario (population variances known) and a more realistic scenario (population variances unknown). In the section 'Example,' we provide a real application of the proposed method. The final section is devoted to the discussion on the HCT trials.
A unified framework
We briefly review the M-S, RCT, and one-sample approaches to HCT sample size calculation. Suppose in a clinical trial, we compare the outcomes between an experimental group and an HC group. The outcome variable is continuous and follows a normal distribution. Let Y 1 , . . . , Y m $ iid Nð 0 , 2 0 Þ be the m observations from the HC group, and X 1 , . . . , X n $ iid Nð 1 , 2 1 Þ be the n observations from the experimental group. We define Y ¼ {Y 1 , . . . , Y m } and X ¼ {X 1 , . . . , X n }. The variances 2 0 and 2 1 are assumed to be known. With null hypothesis H 0 : 1 ¼ 0 and alternative hypothesis H 1 : 1 > 0 , the standard test statistic is
where " X ¼ P n i¼1 X i =n and " Y ¼ P m j¼1 Y j =m are the sample means from the two groups. Given type I error , power 1 À , m, 2 0 , 2 1 , and the difference in treatment effects Á ¼ 1 À 0 , the sample size n is obtained by solving
where z 1À is the 100(1 À )-th percentile of the standard normal distribution. Here and in the rest of this article we do not differentiate the estimated sample size or the solution to the sample size equations, with the understanding that the final sample size is the smallest integer greater than or equal to the solution.
In the M-S approach, the Y j s from the HC group are considered not subject to sampling variability, because they have been observed before the clinical trial. This consideration leads to the following manipulation of Equation (2),
where F(Á) is the cumulative distribution function of the standard normal distribution. Thus we find n by solving
Since the true HC effect ( 0 ) is usually unknown, it is canceled out in the equation by assuming 0 ¼ " Y. This is a strong assumption especially when the number of HC observations is limited. Traditionally, Equation (4) has been solved through a numeric search [11] . Here we present a closedform solution and a sufficient and necessary condition for its existence.
In clinical trials, we usually specify and such that . Equation (4) has a unique sample size solution, if and only if Á>z 1À ffiffiffiffiffiffiffiffiffiffiffi ffi 2 0 =m q , and the solution is
Proof See Appendix A.1. h Theorem 1 helps researchers avoid time-consuming numerical search. It also points out a potential pitfall in the M-S approach, where too small an assumed difference in the treatment effects (Á z 1À ffiffiffiffiffiffiffiffiffiffiffi ffi 2 0 =m q ) would lead to no solution for the sample size.
In the one-sample approach, the hypotheses are specified as H 0 : 1 ¼ " Y and H 1 : 1 > " Y based on the assumption that 0 ¼ "
In the RCT approach, the HC group is treated as a regular control arm in an RCT. The sample size is estimated by
0 , which is based on a two-sample test. The three approaches produce drastically different sample size estimates. For example, given m ¼ 80
, the estimated sample sizes are n 0 ¼ 144, n 1 ¼ 69, and n 2 ¼ 487, respectively. The formulas of n 0 , n 1 , and n 2 do not depend on the specific values of HC sample mean ( " Y) or true mean ( 0 ). The test statistics, however, are calculated based on the HC sample mean. In a particular study, the unknown difference between "
Y and 0 has a great impact on the realized power and type I error. We conduct Simulation 1 to compare the performance of n 0 , n 1 , and n 2 . Details of the simulation algorithm are presented in Appendix A.2.
The realization of a particular HC data (Y (k) ) leads to a conditional power (q ðkÞ v ) and a conditional type I error (h ðkÞ v ) under sample size n v . Over the random realizations of Y, we have a random power, q v , and a random type I error, h v . The distributions of q v and h v provide a global view of the variability in power and type I error for HCTs given an unknown HC treatment effect.
Without loss of generality, we set the true HC effect at 0 ¼ 0. We also assume m ¼ 80 Figure 1 shows the results of Simulation 1. The graphs in the first column indicate that both the conditional power and type I error decrease monotonically as the difference between the observed and true HC treatment effects, ( " Y ðkÞ À 0 ), increases. Table 1 lists the conditional power and type I errors given Y (k) , with "
Y ðkÞ changing between two standard errors below and above 0 . For example, under n 0 , when the observed HC effect ( " Y ðkÞ ) is one standard error away ðAE ffiffiffiffiffiffiffiffiffiffiffi ffi 2 0 =m q Þ from the true effect ( 0 ), the mean power changes from 0.313 to 0.987 and the mean type I error from 0 to 0.088, which deviate far from the nominal levels of 1 À ¼ 0.8 and ¼ 0.05. Note that such a deviation is not a rare event because for a particular HC data set, there is a 32% chance that the sample mean is one standard error or further away from its true mean. The second and third columns of Figure 1 show that the distributions of type I error and power are extremely skewed, which is also revealed by the difference between their means and medians (achieved at " Y ðkÞ ¼ 0 ) in Table 1 .
We briefly explain why the power and type I error have skewed distributions over the random realizations of the HC data. Taking the one-sample Figure 1 The type I errors (h ðkÞ v ) and powers (q ðkÞ v ) under n 0 , n 1 , and n 2 . The first column plots h ðkÞ v and q ðkÞ v vs the difference between the observed and true HC effects, "
Y ðkÞ À 0 , with black for h ðkÞ v and red for q ðkÞ v . The second and third columns plot the histograms of h v and q v , respectively (the vertical axes indicate probability density) approach (n 1 ) for example, for a particular HC data Y (k) , it can be shown that the conditional type I error is
In the parentheses, z 1À is usually the dominant term and shifts the probability computation to the tail area of the normal distribution. As a result, although the sample mean ( " Y ðkÞ ) is symmetric around the true mean ( 0 ), the impact of the sample mean being greater or smaller than the true mean is different. For " Y ðkÞ > 0 , the conditional type I errors have a range of (0, ), which is narrow under commonly specified significance levels. On the other hand, for " Y ðkÞ < 0 , the conditional type I errors have a much wider range, (, 1). In summary, it is because researchers usually set power and significance level in the tail area (i.e., close to 0 and 1 À close to 1) that the random power and type I error are skewly distributed.
Finally, Table 1 provides empirical evidence for the theory presented in Theorem 2, which states a unified framework for n v (v ¼ 0, 1, 2).
Theorem 2
The sample sizes (n 0 , n 1 , and n 2 ) control the random power and type I error in such a way that 1) The M-S approach (n 0 ) controls the mean of type I error at and the median of power at 1 À ;
2) The one-sample approach (n 1 ) controls the medians of type I error and power at and 1 À , respectively; 3) The RCT approach (n 2 ) controls the means of type I error and power at and 1 À , respectively.
Proof See Appendix A.3. h Theorem 2 suggests that the M-S approach tries to reach a compromise between the one-sample and RCT approaches by controlling the mean type I error at and the median power at 1 À .
Sample size controlling the percentiles
Simulation 1 shows that the distributions of power and type I error, observed over all the random realizations of HC data, are extremely skewed. For random variables with extremely skewed distributions, making decisions based on a location parameter such as a percentile is usually more desirable than based on the mean. We propose a sample size formula to control arbitrary percentiles of the random power and type I error. It provides a more sensible way to assess the risk in HCTs.
Theorem 3 Suppose in an HCT the goal is to control the (1 À p q )-th percentile of the power at 1 À , and the p h -th percentile of the type I error at . Then the required sample size is
and the null hypothesis is rejected if
The parameters p q and p h can be specified arbitrarily as long as the condition Á>ðz pq þ z p h Þ ffiffiffiffiffiffiffiffiffiffiffi ffi 2 0 =m q holds.
Proof See Appendix A.4. h
According to Theorem 3, let q* and h* be the random power and type I error under sample size n*, respectively. Then we have P(q* > 1 À ) ¼ p q and P(h* < ) ¼ p h . Suppose an HCT is conducted to assess the effectiveness of a new drug. Given a particular HC data set, the realized power and type I error depend on the random difference between the HC sample mean ( " Y) and its true mean ( 0 ). However, if the researchers enroll n* subjects, they can be confident that over all the possible HC realizations, the power of the clinical trial would be greater than 1 À with probability p q , and the type I error would be smaller than with probability p h . It is easy to check that the sample size under the onesample approach (n 1 ) is a special case of n* at
In other words, we propose sample size n* to achieve the goal that, the operational characteristics (realized power and type I error) of an HCT are more desirable than the nominal levels with certain pre-specified probabilities (p q and p h ). Controlling the power and type I error by percentiles instead of means (the RCT approach) is more effective when their distributions are extremely skewed. Furthermore, the arbitrarily specified p q and p h provide flexibility in accommodating the researchers' preference for risk control.
Based on the same setting as in Simulation 1, we conduct Simulation 2 to explore the properties of n*. We consider different combinations of p q and p h , ranging from 0.5 to 0.9. Table 2 lists the estimated sample size n*, the empirical means of type I error and power, " h Ã ¼ P K k¼1 h ÃðkÞ =K and " q Ã ¼ P K k¼1 q ÃðkÞ =K, and the empirical percentiles,p h ¼ P K k¼1 I ðh ÃðkÞ <Þ=K andp q ¼ P K k¼1 Iðq ÃðkÞ >1 À Þ=K. From Table 2 , we have two observations. First, for sample size calculation, p q and p h are exchangeable in the sense that switching their values leads to the identical sample size, which is also clear from Equation (6) . Second, when the distributions of type I error and power are extremely skewed, it is more sensible to control the percentiles instead of means. For example, under (p h ¼ 0.8, p q ¼ 0.7), we are confident that by enrolling 286 patients, the type I error would be smaller than 0.05 with probability 0.8, and the power would be greater than 0.8, with probability 0.7. It provides a high assurance for researchers. Note that in this case the mean power is 0.8, but the mean type I error is 0.06, slightly higher than the nominal ¼ 0.05. As demonstrated in Table 1 , the required sample size is n 2 ¼ 487 (under the RCT approach) if we control the mean power and mean type I error at 0.8 and 0.05, respectively. That is, in order to reduce the mean type I error from 0.06 to 0.05, the researchers need to enroll 201 additional patients, due to the skewness in the type I error distribution.
In Simulations 1 and 2, we have assumed the population variances of the HC and experimental groups ( 2 0 and 2 1 ) to be known, which is usually unrealistic in practice. We conduct Simulation 3 to further assess the performance of n* in a more realistic scenario. It proceeds as follows: (a) To compute the required sample size n*, the assumed Á and 2 1 will be plugged into Equation (6) . However, 2 0 is replaced by s 2 0 , the HC sample variance. (b) In hypothesis testing, we compute the test statistic Z*(X, Y) with 2 0 replaced by s 2 0 , and 2 1 replaced by s 2 1 , the sample variance in the experimental group. Thus the estimated sample size The estimated sample size n*, the average empirical type I errors and empirical powers, ( " h Ã , " q Ã ), and the realized controlling percentiles, ½p h ,p q , under different combinations of p h and p q . We assume that m ¼ 80 includes additional uncertainty from s 2 0 , and the test statistic includes additional uncertainty from s 2 0 and s 2 1 . The detailed algorithm of Simulation 3 is presented in Appendix A.5. Table 3 lists the results of Simulation 3. The sample size n* becomes random when we replace the HC population variance ( 2 0 ) with a random sample variance (s 2 0 ). When p q ¼ p h ¼ 0.5, the impact of the additional randomness is negligible. That is, after applying the integer restriction on sample size, the calculated n* is constant at 69, the same as its counterpart in Table 2 . As p q or p h increases, the standard deviation of n* increases, and the mean of n* deviates from the fixed sample size (in Table 2 ) computed under the population variance. This is because under large p q and p h , the distribution of n* is heavily skewed to the right. Such skewness also arises from the tail behavior of the normal distribution. For example, under (p q ¼ 0.9, p h ¼ 0.8), the random sample size has a mean of 3065.59 and a standard deviation of 29348.36. Its distribution has an extremely long tail (the 99th percentile is greater than 200,000). The skewness is much more severe under (p q ¼ p h ¼ 0.9), where we omit the simulation due to computer overflow. On the other hand, the operational characteristics of the clinical trial remain unchanged with additional randomness from the sample variances. Specifically, the realized controlling percentiles,p h andp q , agree with the nominal levels. Furthermore, the means of power and type I error are close to those (in Table 2 ) obtained under the population variances.
Taken together, the proposed sample size n* successfully controls the percentiles of power and type I error even when the population variances are unknown.
Example
The safety and efficacy of laparoscopic rectopoxy for rectal prolapse will be compared with those of open rectopexy procedure, which was conducted several months ago by the same group of surgeons at the same institution [16] . Data will be collected prospectively for the laparoscopic rectopoxy group and by hospital chart review for the HC group. The HC group includes 24 consecutive patients who had undergone conventional open rectopexy without having concomitant gynecologic procedures. These patients required an average of 71.5 mg of morphine during the first 48 h after procedure with a standard deviation of 45.9 mg. It is expected that the average amount of morphine needed during the first 48 h of laparoscopic rectopexy will be 41.5 mg with a standard deviation of 35.0 mg. We estimate the number of patients needed to detect the difference between open and laparoscopic procedures in morphine requirement during the first 48 h between open and laparoscopic procedures, controlling the 70th percentile (p h ¼ 0.7) of type I error at 5%, and the 30th percentile (p q ¼ 0.7) of power at 80%. The numbers of patients needed in the laparoscopic group are n 0 ¼ 14 (the M-S The estimated mean (standard deviation) of n*, the average empirical type I errors and empirical powers, ( " h Ã , " q Ã ), and the realized controlling percentiles, ½p h ,p q , under different combinations of p h and p q . We assume that m ¼ 80, 2 0 ¼ 2 1 ¼ 1, Á ¼ 0:3, ¼ 0:05, 1 À ¼ 0.8, and the population variances ( 2 0 and 2 1 ) are unknown. approach), n 1 ¼ 9 (the one-sample approach), n 2 ¼ 22 (the RCT approach), and n* ¼ 19 (the proposed approach), respectively. Note that the above sample sizes are obtained by replacing the unknown HC population variance with the sample variance.
Discussion
We have provided a unified framework for three existing approaches (M-S, one sample, and RCT) in HCTs, by showing that they either control the mean or the median of power and type I error. We further developed a closed-form sample size formula to control arbitrary percentiles of the random power and type I error. It provides more flexibility in assessing the risk in HCTs and accommodates the extreme skewness in the distributions of power and type I error. We limited our discussion to the HCTs with continuous outcomes. In the future we will extend it to HCTs with binary and survival time outcomes. Similar to the existing approaches, the proposed sample size formula (n*) requires the population variances of the HC and the experimental group to be known. Through simulation study, we demonstrated that the proposed approach successfully controls the percentiles of power and type I error in a more realistic scenario, where the true variances are unknown and they are replaced with observed sample variances.
Lee and Tseng [14] presented sample size calculation for HCTs with binary outcomes controlling the means of power and type I error. Theorem 2 states that the same goal is achieved by n 2 for HCTs with continuous outcomes. The computation in reference [14] is more complicated due to the transformation performed on binary data. For continuous outcomes, when the HC variance is assumed to be known, the sample size formula does not depend on observations from the HC group. Thus one pair of null and alternative hypotheses leads to one unique sample size estimate. For binary outcomes, the sample size formula computed under the arcsin transformation depends on the observations from the HC group. Thus one pair of hypotheses leads to many possible sample size estimates, each determined by a random realization of the HC data. In reference [14] , the authors had to deal with the expectation of the sample sizes.
The term ð " Y þ z p h ffiffiffiffiffiffiffiffiffiffiffi ffi 2 0 =m q Þ in the numerator of Z*(X, Y) is the p h -th percentile of posterior distribution [ 0 | Y] under a flat prior, which suggests a potential connection of the proposed approach to a Bayesian sample size calculation. Nonetheless, in Appendix A.4., the derivation of n* is strictly in the frequentist paradigm, where the randomness of type I error and power comes from the uncertainty in the HC data Y, not from random variable 0 (as in a Bayesian method). For example, we set type I error h* ¼ at "
From (7) we can find a closed-form solution for ffiffiffi n p , subject to the constraint that ffiffiffi n p >0. First we need b 2 À 4ac ! 0, where a, b and, c are defined in (5) . This condition implies
q , and two possible roots
:
, then a ¼ 0, and the solution to (7) is r ¼ Àc/b. Because c > 0 when < and b > 0 by definition, we eliminate r due to the positive constraint on ffiffiffi n p . . There are two scenarios:
. It is eliminated due to Fact 1.
2) b 2 À 4ac > 0 and r 1 < 0 and r 2 > 0. Note that the condition b 2 À 4ac > 0 implies The superscript (k) of h ðkÞ v and q ðkÞ v suggests that they are computed given the kth simulated HC data. We set
Proof of Theorem 2
Proof We first state the fact that " Y $ Nð 0 , 2 0 =mÞ, "
YÞ ¼ 0 . For n 0 and n 2 , the null hypothesis is rejected if Z(X, Y) > z 1À . Marginalizing with respect to Y is equivalent to marginalizing with respect to " Y. Thus for v ¼ 0, 2,
We have the third equality through random variable transformation, where
and it is easy to show that U v $ N(0, 1).
In the similar fashion, we can show that E(q 2 ) ¼ 1 À ,
We have the second equality by defining
The third equality is obtained by plugging the expression of n 2 and recognizing U $ N(0, 1).
We then show that median (q 0 ) ¼ 1 À . From Equation (3) we have First, we recognize that q ðkÞ 0 is a decreasing function of " Y ðkÞ . Second, n 0 is the solution to q ðkÞ 0 ¼ 1 À by setting " Y ðkÞ ¼ 0 ¼ median ð " YÞ. These two points lead to the conclusion that median (q 0 ) ¼ 1 À . Note that E (q 2 ) and q ðkÞ 0 have different expressions because the former marginalizes with respect to random " Y, while the latter is defined conditional on a particular Y (k) . Now we show that median (h 1 ) ¼ , Thus h ðkÞ 1 is a decreasing function of " Y ðkÞ and h ðkÞ
YÞ. Thus we conclude that median (h 1 ) ¼ . Similar argument leads to the conclusion that median (q 1 ) ¼ 1 À . h Appendix A.4
Proof of Theorem 3
Proof First we demonstrate that based on Z*(X, Y), the p h -th percentile of type I error is controlled at : For a given " Y, the type I error is
Thus h* ¼ when " Y ¼ 0 À z p h ffiffiffiffiffiffiffiffiffiffiffi ffi 2 0 =m q , which is the (1 À p h )-th percentile of " Y $ Nð 0 , 2 0 =mÞ. Together with the fact that h* is a monotonically decreasing function in " Y, we have Pðh Ã <Þ ¼ Pð " Y> 0 À z p h ffiffiffiffiffiffiffiffiffiffiffi ffi 2 0 =m q Þ ¼ p h . Note that this statement holds for any n*.
Then we solve for n* which controls the (1 À p q )-th percentile of power at 1 À : the
